NephroGenex, Inc. Reports Year-End 2013 Financial Results
March 31, 2014 08:00 ET
|
NephroGenex, Inc.
Raised over $37 million in gross proceeds during Feb. 2014 Initial Public Offering
Obtained SPA for shortened Phase 3 PIONEER clinical program in diabetic nephropathy
Entered...
NephroGenex Announces Research Collaborations for Pivotal Studies of Pyridorin(TM) in Diabetic Nephropathy
March 27, 2014 08:00 ET
|
NephroGenex, Inc.
RESEARCH TRIANGLE PARK, N.C., March 27, 2014 (GLOBE NEWSWIRE) -- NephroGenex, Inc.(Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today...
NephroGenex Announces Closing of Initial Public Offering
February 14, 2014 11:30 ET
|
NephroGenex, Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 14, 2014 (GLOBE NEWSWIRE) -- NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today...
NephroGenex Prices Initial Public Offering of Common Stock
February 10, 2014 18:49 ET
|
NephroGenex, Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2014 (GLOBE NEWSWIRE) -- NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today...